Skip to main content

Advertisement

SpringerLink
Log in

Which children with idiopathic short stature should receive growth hormone therapy?

  • Viewpoint
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rappold G et al. (2002) Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab 87: 1402–1406

    Article  CAS  PubMed  Google Scholar 

  2. Shanske AL et al. (2007) Unique deletion in exon 5 of SHOX gene in a patient with idiopathic short stature. Horm Res 67: 61–66

    CAS  PubMed  Google Scholar 

  3. Hintz RL et al. (1999) Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med 340: 502–507

    Article  CAS  PubMed  Google Scholar 

  4. Kemp SF et al. (2005) Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 90: 5247–5253

    Article  CAS  PubMed  Google Scholar 

  5. Leschek EW et al. (2004) Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 89: 3140–3148

    Article  CAS  PubMed  Google Scholar 

  6. van Dijk M et al. (2007) Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab 92: 160–165

    Article  CAS  PubMed  Google Scholar 

  7. Ross JL et al. (2004) Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab 89: 4873–4878

    Article  CAS  PubMed  Google Scholar 

  8. Dickinson HO et al. (2007) Self-reported quality of life of 8–12-year-old children with cerebral palsy: a cross sectional European study. Lancet 369: 2171–2178

    Article  PubMed  Google Scholar 

  9. Ranke MB et al. (2007) Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res 68: 53–62

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Hopital Necker Enfants Malades, 149 rue de Sevres, Paris 75015, France paul.czernichow@nck.aphp.fr

Authors and Affiliations

  1. P Czernichow is a Professor of Paediatrics and a Consultant in Endocrinology and Diabetes, Hopital Necker Enfants Malades, Paris, France.,

    Paul Czernichow

Authors
  1. Paul Czernichow
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Czernichow is a consultant for Ipsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czernichow, P. Which children with idiopathic short stature should receive growth hormone therapy?. Nat Rev Endocrinol 4, 118–119 (2008). https://doi.org/10.1038/ncpendmet0700

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0700

  • Springer Nature Limited

Search

Navigation